A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors
- Advanced-stage Solid Tumors
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 360
- Started
- 10 October 2025
- Main results due
- 15 December 2026
- Study sites
- 6
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening * Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom Exclusion Criteria: * Active central nervous system (CNS) involvement unless clinically stable * History of clinically significant cardiovascular disease within 6 months prior to signing informed consent * History of solid organ or hematologic stem cell transplantation * Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175 * Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Study sites(6)
AdventHealth Orlando
Orlando, Florida, United States
Recruiting
NEXT Oncology
Irving, Texas, United States
Recruiting
Centre Leon Berard
Lyon, France
Recruiting
Gustave Roussy
Villejuif, France
Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea
Recruiting
Samsung Medical Center
Seoul, South Korea
Recruiting
Showing 6 of 6 sites. 6 of the 6 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07223125. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me